3상모집 중
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
연구 개요
This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.
- 스폰서
- 협력: 리제네론
- 적응증
- Multiple Myeloma
- 중재
- Linvoseltamab, Daratumumab, Lenalidomide, Dexamethasone
- 목표 등록
- 1,000명
- 시작일
- 2025-12-23
- 완료(예정)
- 2036-12-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.